Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
No. On current human evidence, AOD-9604 is not as good as GLP-1 drugs for weight loss: its best trials showed about 2.6–2.8 kg over 12 weeks and failed confirmation, while semaglutide and tirzepatide produced 15–21% sustained loss. AOD-9604 is also FDA Category 2, not approved.
AOD-9604 is not as effective for weight loss as GLP-1 drugs, based on current human evidence. In the largest published trials, AOD-9604 produced roughly 2.6–2.8 kg of weight loss over 12 weeks and failed its pivotal endpoint, while semaglutide and tirzepatide drove 15–21% body-weight reductions. AOD-9604 also remains FDA Category 2 and is not approved.
AOD-9604 vs GLP-1 at a glance
| Feature | AOD-9604 | GLP-1 / GIP-GLP-1 drugs (semaglutide, tirzepatide) |
|---|---|---|
| Class | Modified C-terminal fragment of human growth hormone (residues 176–191) | Incretin receptor agonists (GLP-1; tirzepatide adds GIP) |
| Mechanism | Stimulates lipolysis and fat oxidation in adipose tissue; does not act on appetite | Suppresses appetite centrally, slows gastric emptying, increases satiety |
| Best human result | ~2.6–2.8 kg over 12 weeks (early trials); pivotal trial missed endpoint | −14.9% (semaglutide, 68 wk); up to −20.9% (tirzepatide, 72 wk) |
| Typical research dose | Research literature cites ~1 mg/day (oral or subcutaneous in trials) | Semaglutide 2.4 mg/week; tirzepatide 5–15 mg/week (subcutaneous) |
| Appetite effect | None demonstrated | Strong appetite suppression |
| FDA status | Not approved; Category 2 on 503A interim bulks list | FDA-approved for chronic weight management |
| Key side effects (trials) | Well tolerated; profile near placebo | GI effects (nausea, vomiting, diarrhea), common and dose-related |
What is AOD-9604 and what is a GLP-1 drug?
AOD-9604 and GLP-1 receptor agonists are frequently mentioned in the same breath as "weight-loss peptides," but they are fundamentally different molecules with different mechanisms, different evidence bases, and very different regulatory standing. Understanding that difference is the whole point of this comparison.
AOD-9604 is a synthetic peptide corresponding to amino acids 176–191 of the C-terminus of human growth hormone (hGH), with a tyrosine residue added to the N-terminus to improve stability. It was developed by Metabolic Pharmaceuticals (Australia) specifically to isolate the fat-metabolizing "lipolytic domain" of growth hormone while leaving out the parts of the molecule responsible for growth-promoting and blood-sugar effects. In preclinical work, AOD-9604 reduced body-weight gain in obese rodents without impairing insulin sensitivity (Ng et al., 2000, Horm Res).
GLP-1 drugs are a class of incretin-based medicines. Semaglutide (Wegovy, Ozempic) is a GLP-1 receptor agonist; tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist. Rather than acting on fat cells directly, they work largely through the brain and gut — reducing appetite, increasing satiety, and slowing gastric emptying (Liu et al., 2024, Front Endocrinol). These are FDA-approved prescription drugs with large phase 3 trial programs behind them.
The shorthand version: AOD-9604 tries to make fat cells burn more fat. GLP-1 drugs make you eat less. That mechanistic gap explains nearly every difference in the table above.
For deeper background on each compound, see our AOD-9604 protocol guide and semaglutide protocol guide.
How does AOD-9604 work compared to GLP-1 drugs?
The mechanisms are almost mirror opposites, which matters because it shapes both how much weight each can move and what side effects come along for the ride.
AOD-9604 acts on adipose tissue, not appetite. In rodent studies, AOD-9604 increased in vivo fat oxidation and raised plasma glycerol — a marker of lipolysis (fat breakdown) — and reduced body-weight gain in obese mice, comparably to full-length growth hormone but without inducing hyperglycemia or reducing insulin secretion (Heffernan et al., 2001, Int J Obes Relat Metab Disord, PMID 11673763). A companion study found that AOD-9604 chronically upregulated beta-3 adrenergic receptor (β3-AR) expression in fat tissue; in β3-AR knockout mice, chronic treatment no longer produced weight loss, implicating β3-AR signaling in the sustained effect (Heffernan et al., 2001, Endocrinology, 142(12):5182–5189). Critically, AOD-9604 does not bind the growth-hormone receptor and, in human safety studies, did not raise IGF-1 or impair glucose tolerance (Stier et al., 2013, J Endocrinol Metab). It has no demonstrated effect on appetite.
GLP-1 drugs act on the brain and gut. GLP-1 receptor agonists reduce food intake primarily through central GLP-1 receptors in the hypothalamus and brainstem satiety centers, slow gastric emptying, and enhance the feeling of fullness; tirzepatide adds GIP-receptor activity that appears to potentiate the appetite- and weight-reducing effect (Liu et al., 2024, Front Endocrinol). The weight loss is driven by a meaningful, sustained reduction in calories consumed.
This is the core reality check: a drug that suppresses appetite has a much larger lever on energy balance than a peptide that nudges fat cells toward oxidation. In practice, eating several hundred fewer calories a day for months tends to outweigh a modest increase in fat-burning capacity.
Consult your healthcare provider before considering any peptide or weight-management medication.
Does AOD-9604 actually work for weight loss in humans?
This is the question the search query "aod-9604 weight loss" is really asking, and the honest answer is: the human evidence is weak and ultimately did not support clinically meaningful fat loss.
AOD-9604 went through a full clinical program. A pooled safety review covering six randomized, double-blind, placebo-controlled trials with roughly 900 adults concluded that AOD-9604 had "a very good safety and tolerability profile indistinguishable from placebo," with no serious adverse events, no anti-drug antibodies, no IGF-1 elevation, and no adverse effect on glucose tolerance (Stier et al., 2013, J Endocrinol Metab). On safety, AOD-9604 looked clean.
On efficacy, the story is much less encouraging:
- In an earlier 12-week phase 2 study, the best-performing 1 mg dose group lost an average of about 2.8 kg versus about 0.8 kg on placebo — statistically significant, but a small absolute difference (publicly reported phase 2 results; figures should be confirmed against the primary trial report [VERIFY: exact kg values and dose group from primary publication]).
- The larger, longer pivotal phase 2b program did not reproduce that signal. Development of AOD-9604 as a weight-loss drug was halted in 2007 after a longer trial — which incorporated an intensive diet-and-exercise regimen — failed to show significant weight loss versus placebo. The early benefit "was not seen in the last study in which an intensive diet and exercise regime was incorporated" [VERIFY: exact participant count and duration of the terminated pivotal trial].
In other words, when AOD-9604 was tested under the more rigorous conditions that approval would require, it did not beat placebo. The compound was never approved as a weight-loss drug anywhere, and the developer pivoted toward exploring it as a nutraceutical/osteoarthritis ingredient instead.
Compare that to the GLP-1 head-to-head benchmarks, both from large phase 3 trials:
- Semaglutide 2.4 mg/week produced a mean −14.9% body-weight change at 68 weeks versus −2.4% with placebo in STEP 1, with 86% of participants losing at least 5% of body weight (Wilding et al., 2021, N Engl J Med, 384:989–1002, PMID 33567185).
- Tirzepatide produced mean weight changes of −15.0%, −19.5%, and −20.9% at the 5, 10, and 15 mg doses respectively over 72 weeks, versus −3.1% with placebo, in SURMOUNT-1 (Jastreboff et al., 2022, N Engl J Med, 387:205–216, PMID 35658024).
The gap is not subtle. The best human AOD-9604 result is a few kilograms over three months that didn't hold up in confirmatory testing; the GLP-1 results are 15–21% sustained weight loss across thousands of participants. By the standard of "does it work for weight loss," GLP-1 drugs are in a different category of evidence.
Consult your healthcare provider before starting any peptide protocol.
When might someone consider AOD-9604 vs a GLP-1 drug?
Because Peptides.NYC is educational and does not prescribe, this section is about how the evidence maps onto different scenarios — not a recommendation to use any compound.
| Scenario | What the evidence points toward |
|---|---|
| Goal is substantial, proven weight loss | The high-quality human evidence sits entirely with GLP-1/GIP drugs (15–21% in phase 3 trials). AOD-9604 has no comparable efficacy data. |
| Cannot tolerate GLP-1 GI side effects | This is a real clinical problem, but it's a question for a prescriber — switching to an unapproved peptide with no proven efficacy is not an evidence-based substitute. |
| Interested in AOD-9604's research safety profile | AOD-9604's safety signal in trials was reassuring, but "safe and ineffective" is still ineffective for a weight-loss goal. |
| Considering AOD-9604 for joint/recovery research interest | Some later research explored AOD-9604 in cartilage/osteoarthritis contexts; that is a separate, also-unproven use and outside the scope of weight loss. |
| Wants something legal and FDA-vetted | GLP-1 drugs are FDA-approved; AOD-9604 is FDA Category 2 and not approved (see regulatory section). |
The recurring theme: there is no weight-loss scenario in which the published human data favor AOD-9604 over an approved GLP-1 drug. Where AOD-9604 comes up is usually cost, access, or side-effect avoidance — none of which change the fact that its efficacy was never established.
For goal-based context, see our fat-loss peptides hub and GLP-1 peptides hub.
How do the side effects of AOD-9604 and GLP-1 drugs compare?
| Side-effect domain | AOD-9604 | GLP-1 / GIP-GLP-1 drugs |
|---|---|---|
| Gastrointestinal | Not prominent in trials | Nausea, vomiting, diarrhea, constipation — the most common adverse events, usually dose-related and most intense during escalation |
| Blood sugar / insulin | No adverse effect on glucose tolerance in trials; no IGF-1 elevation (Stier et al., 2013) | Improves glycemic control; hypoglycemia risk rises if combined with insulin/sulfonylureas |
| Injection-site / tolerability | Generally well tolerated; profile near placebo across ~900 subjects (Stier et al., 2013) | Injection-site reactions; gallbladder events and pancreatitis are labeled risks |
| Serious adverse events | None attributed in the pooled safety review (Stier et al., 2013) | Boxed warning for thyroid C-cell tumors (rodent finding); contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2 |
| Long-term human safety | Limited; program ended ~2007, so long-term data are sparse | Extensive trial and post-market data across large populations |
Two honest caveats here. First, AOD-9604's clean safety profile is partly a function of how little it did — a compound that barely moves the needle metabolically also has fewer ways to cause harm. Second, AOD-9604's long-term human safety is genuinely under-characterized because development stopped nearly two decades ago; "no signal in short trials" is not the same as "proven safe long-term." GLP-1 drugs carry more frequent and sometimes serious side effects, but those risks are also far better quantified.
Safety claims here are drawn from published trials and FDA labeling; individual risk varies. Consult your healthcare provider before starting any peptide or medication.
How much do AOD-9604 and GLP-1 drugs cost, and can you get them legally?
This is where the comparison gets sharpest in 2026, because regulatory status — not just price — determines access.
GLP-1 drugs are FDA-approved prescription medications. They are expensive (often roughly $1,000+/month at list price for branded products, with wide variation by insurance, manufacturer savings programs, and formulation), but they are legally prescribed, pharmacy-dispensed, and quality-controlled.
AOD-9604 is not FDA-approved for any use and is not a legally marketed drug. Its regulatory standing for compounding is the critical fact in 2026:
- AOD-9604 is currently in Category 2 on the FDA's interim list of bulk drug substances used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Category 2 means FDA has identified significant safety questions and the substance is not eligible for routine 503A compounding while in that bin (FDA, Bulk Drug Substances Used in Compounding Under Section 503A).
- At the December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting, FDA recommended that AOD-9604 (free base) and AOD-9604 acetate not be added to the 503A bulks list, citing concerns including insufficient human safety data and a lack of reproducible efficacy; PCAC voted in line with that recommendation (FDA PCAC, December 2024) [VERIFY: exact PCAC vote tally].
- AOD-9604 is not among the seven peptides scheduled for FDA's next PCAC review on July 23–24, 2026 (that docket covers BPC-157, KPV, TB-500, MOTS-C, DSIP/emideltide, Semax, and Epitalon). So no near-term reclassification of AOD-9604 is on the calendar.
Quick primer on the regulatory terms:
- 503A governs traditional compounding pharmacies making patient-specific preparations.
- 503B governs "outsourcing facilities" that compound at larger scale; it maintains a separate bulks list.
- A substance in Category 1 may be used in compounding while FDA evaluates it; Category 2 substances are effectively off-limits pending resolution of safety concerns.
Practically, this means AOD-9604 sold online is almost always labeled "for research use only," is not made to pharmaceutical standards, and is not legally available as a compounded therapeutic in the United States. That research-only gray market carries real risks: no guarantee of identity, purity, dose accuracy, or sterility.
Legal status varies by jurisdiction; consult a lawyer for binding advice, and consult your healthcare provider before considering any peptide. For a fuller breakdown, see our guide to peptide legality and the 503A/503B lists.
Can you stack AOD-9604 with a GLP-1 drug?
You may see "AOD-9604 + GLP-1" stacks promoted online, with the theory that the GLP-1 cuts calories while AOD-9604 preserves or accelerates fat oxidation. The honest assessment: there is no human trial evidence that adding AOD-9604 to a GLP-1 regimen improves fat loss, preserves lean mass, or does anything measurable.
A few points worth being clear about:
- The mechanisms are non-overlapping (appetite vs. lipolysis), so a theoretical additive effect isn't crazy — but theory is not data, and AOD-9604 didn't reliably work even on its own.
- Combining an FDA-approved drug with an unapproved, research-grade peptide of unknown purity introduces uncertainty in both safety and quality, and it is not something a clinician can evaluate from controlled-trial evidence because that evidence doesn't exist.
- Lean-mass preservation during GLP-1 weight loss is a legitimate and active research question, but the better-studied levers are resistance training and adequate protein intake — not AOD-9604.
If lean-mass preservation is your concern, that is a conversation to have with a healthcare provider, not a reason to add an unproven peptide. Consult your healthcare provider before combining any compounds. For a related comparison, see tesamorelin vs AOD-9604.
The bottom line: is AOD-9604 as good as GLP-1 for weight loss?
No — not on the evidence. AOD-9604 is a well-tolerated peptide with a plausible fat-burning mechanism in animals, but its human weight-loss data are thin, its best results were modest and not reproduced in confirmatory trials, and its development as a weight-loss drug was abandoned in 2007. GLP-1 and GIP/GLP-1 drugs, by contrast, have produced 15–21% sustained weight loss across large phase 3 trials and are FDA-approved.
If the goal is meaningful, evidence-based weight loss, the published science points decisively to GLP-1-class drugs. AOD-9604 is interesting research history and a Category 2 compound — not a proven GLP-1 alternative.
Consult your healthcare provider before starting, stopping, or changing any weight-management protocol.
Frequently asked questions
Q: Is AOD-9604 as effective as semaglutide or Ozempic for weight loss? A: No, based on current human evidence. AOD-9604's best published result was roughly 2.6–2.8 kg of weight loss over 12 weeks in early trials, and even that signal disappeared in a longer confirmatory study, leading the developer to halt the weight-loss program in 2007. Semaglutide 2.4 mg/week produced a −14.9% mean body-weight change over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM). The two are not in the same evidence tier. Discuss any weight-loss plan with a healthcare provider.
Q: How does AOD-9604 work differently from a GLP-1 drug? A: AOD-9604 acts on fat cells — in animal models it stimulates lipolysis (fat breakdown) and fat oxidation and upregulates beta-3 adrenergic receptors, without binding the growth-hormone receptor or affecting blood sugar (Heffernan et al., 2001). GLP-1 drugs act mainly on the brain and gut, suppressing appetite, slowing gastric emptying, and increasing satiety (Liu et al., 2024). Appetite suppression is a much larger lever on weight than fat-cell stimulation, which is the core reason GLP-1 drugs produce far more weight loss.
Q: Why was AOD-9604 never approved as a weight-loss drug? A: Its pivotal clinical testing failed to demonstrate clinically meaningful weight loss versus placebo. A pooled review of six trials in ~900 adults confirmed excellent safety, but the longer, more rigorous trial — which added an intensive diet-and-exercise regimen — did not reproduce the modest early benefit, and development as an obesity drug stopped around 2007 (Stier et al., 2013). It was never approved for weight loss in any country.
Q: Is AOD-9604 legal in 2026? A: AOD-9604 is not FDA-approved and currently sits in Category 2 on the FDA 503A interim bulks list, meaning it is not eligible for routine compounding due to identified safety concerns. At the December 2024 PCAC meeting, FDA recommended against adding it to the 503A list. It is not among the peptides scheduled for the July 23–24, 2026 PCAC review. Products sold online are typically labeled "research use only." Legal status varies by jurisdiction; consult a lawyer for binding advice.
Q: Can I take AOD-9604 with semaglutide or tirzepatide? A: There is no human trial evidence that stacking AOD-9604 with a GLP-1 drug improves results or is safe. The mechanisms don't overlap, so an additive effect is theoretically possible, but theory isn't data — and AOD-9604 didn't reliably work alone. Combining an approved drug with an unapproved, research-grade peptide also adds quality and safety uncertainty. Talk to your healthcare provider before combining any compounds.
Q: Does AOD-9604 cause the nausea that GLP-1 drugs do? A: No. In clinical trials, AOD-9604 was well tolerated with a side-effect profile close to placebo and no prominent gastrointestinal effects (Stier et al., 2013). GLP-1 drugs commonly cause dose-related nausea, vomiting, and diarrhea, especially during dose escalation. However, AOD-9604's gentler profile partly reflects how little it does metabolically, and its long-term human safety is under-studied. Consult your healthcare provider before starting any compound.
Q: Is AOD-9604 the same as HGH fragment 176-191? A: They are closely related but not identical. HGH fragment 176-191 is the natural C-terminal lipolytic region of human growth hormone. AOD-9604 is that fragment with an added N-terminal tyrosine residue, a modification made to improve stability and lipolytic potency in preclinical testing (Ng et al., 2000). Both are studied for fat metabolism, and neither is FDA-approved for weight loss.
References
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274–278. PMID: 11146367. https://pubmed.ncbi.nlm.nih.gov/11146367/
- Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442–1449. PMID: 11673763. https://pubmed.ncbi.nlm.nih.gov/11673763/
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189. https://academic.oup.com/endo/article/142/12/5182/2988749
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1–2):7–15. https://www.jofem.org/index.php/jofem/article/view/157/194
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PMID: 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol. 2024;15:1431292. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1431292/full
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (interim policy; Category 1/Category 2 lists). Accessed June 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) Meeting Materials, December 4, 2024 (AOD-9604 free base and acetate review). https://www.fda.gov/media/184043/download
- U.S. Food and Drug Administration. Federal Register notice — Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 (peptide docket). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.